Navigation Links
New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
Date:4/7/2008

KGK Synergize Inc. Presents Findings Today

SAN DIEGO, April 7, 2008 /PRNewswire/ -- A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol(TM), produces a pronounced reduction of malignant melanoma cell growth. Dermytol(TM), a proprietary compound developed by KGK Synergize Inc., a biotechnology company in Ontario Canada, is designed to protect skin cells from damage that may lead to skin cancer.

Mal Evans, DVM, MSc, PhD, KGK Synergize Inc.'s Scientific Director, said, "Skin cancer rates have been rising, and we are likely to see that continue as the population ages. The National Cancer Institute (NCI) estimates that more than 62,000 Americans will be diagnosed with melanoma and one million Americans will be diagnosed with non-melanoma skin cancer this year. NCI expects more than 8,000 deaths from melanoma and less than 1,000 deaths from non-melanoma cancers this year.

"Dermytol(TM) has the potential to be used in anti-aging and sun-protection products to reduce damage to skin. Results of preclinical trials in animals have been promising leading to human trials now running in both Canada and the United States.

In the most recent study, male mice were fed either a Dermytol(TM)-canola oil mixture or just canola oil. In a separate part of the study, researchers applied either a Dermytol(TM) cream or a placebo cream onto the shaved skin of a different group of mice. After seven days of treatment, all of the mice were injected with malignant melanoma tumor cells. Dermytol(TM) or placebo treatments continued for 25 days.

The mice in both Dermytol(TM) groups benefited from their treatments. Compared to the controls, the orally treated mice showed an average decrease in tumor size by about 45 percent. The mice receiving the topical treatment benefited even more with a 61 percent decrease in tumor volume.

In this study and previous preclinical studies, Dermytol(TM) produced no adverse effects.

In a laboratory cell culture study, Dermytol(TM) inhibited the proliferation of human cancer cells.

In another study, dietary supplementation with Dermytol(TM) moderately delayed the onset of skin tumors and significantly reduced tumor growth rate in mice treated to induce non-melanoma skin cancers.

A trial involving 45 subjects with actinic keratoses -- precancerous skin lesions -- is underway. "The current treatment for actinic keratoses is removal by freezing which can be painful or the application of a cream that causes inflammation and blistering of the skin," said Evans. "We expect Dermytol(TM) to be a welcome option."

About KGK Synergize Inc:

KGK Synergize provides contract research services to the health nutrition, biotechnology and pharmaceutical industries which include analytical chemistry, in vitro assays, in vivo models, toxicology and human clinical trials.

In addition to its contract research capabilities, KGK has a Product Development Division, which brings new and innovative natural health products to the point where they are ready to be manufactured and marketed. These products include Sytrinol(TM) for cardiovascular health, Diabetinol(TM) for the treatment and/or prevention of Type II Diabetes, and Dermytol(TM), a new product for the protection of sun damage to the skin.


'/>"/>
SOURCE KGK Synergize Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
2. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
3. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
4. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
5. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
6. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
7. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
8. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
9. Study Finds Repeated Episodes of Stent Thrombosis Common
10. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery
11. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
Breaking Medicine News(10 mins):